Literature DB >> 1415496

Traumatic perilymphatic fistula: how long can symptoms persist? A follow-up report.

M E Glasscock1, M J Hart, J D Rosdeutscher, S A Bhansali.   

Abstract

In the past 18 years 68 ears (average 3.8 per year) were explored for perilymphatic fistula (PLF). A total of nine (13%) ears had a fistula identified at operation. Patients with a previous history of otologic surgery were excluded from this review. The most common etiology for PLF was head trauma (4 of 9). Most patients had persistent symptoms lasting months (average 6.7). Eighty-three percent of all patients had sudden or fluctuating hearing loss, 77 percent had vertigo or dysequilibrium, and 61 percent had tinnitus. Vertigo was the most commonly improved symptom postoperatively, and only 25 percent of patients had improved hearing. There were no major complications. The authors discuss indications for operation, criteria for diagnosis of PLF, and audiometric and electronystagmographic findings. This report agrees with other recent data indicating that exploration for fistula is an uncommon procedure performed by otologists.

Entities:  

Mesh:

Year:  1992        PMID: 1415496

Source DB:  PubMed          Journal:  Am J Otol        ISSN: 0192-9763


  4 in total

Review 1.  Perilymphatic fistula.

Authors:  C G Maitland
Journal:  Curr Neurol Neurosci Rep       Date:  2001-09       Impact factor: 5.081

2.  [Post-traumatic diagnosis of unilateral deafness].

Authors:  R Kunz; W Stoll; M Freund; C Gaus; F Schmäl
Journal:  HNO       Date:  2002-07       Impact factor: 1.284

3.  Effects of early surgical exploration in suspected barotraumatic perilymph fistulas.

Authors:  Ga Young Park; Hayoung Byun; Il Joon Moon; Sung Hwa Hong; Yang-Sun Cho; Won-Ho Chung
Journal:  Clin Exp Otorhinolaryngol       Date:  2012-06-12       Impact factor: 3.372

4.  Post-traumatic peripheral vestibular disorders (excluding positional vertigo) in workers following head injury.

Authors:  Priyanka Misale; Fatemeh Hassannia; Sasan Dabiri; Tom Brandstaetter; John Rutka
Journal:  Sci Rep       Date:  2021-12-06       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.